ArticleZoonoses and public health2025
Canine Spotted Fever Group Rickettsial Seroprevalence as an Indicator for Human Rocky Mountain Spotted Fever Case Rates in Arizona, USA.
Article in Zoonoses and public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cross-protective immunity from inactivated whole cellResearch square · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionRocky Mountain spotted fever (RMSF), a rapidly progressing febrile disease caused by the bacterium Rickettsia rickettsii, is the deadliest tick-borne disease in the world. Human infection initially results in non-specific symptoms and, if untreated, can result in death in up to 35% of cases. Rhipicephalus sanguineus (brown dog tick) was discovered to spread RMSF in Arizona and Northern Mexico in the early 2000s, and the disease is now considered endemic in areas of the Southwestern United States. This study investigates the relationship between canine spotted fever group rickettsial (SFGR) seroprevalence and human RMSF case rates in Arizona.
methodsCanine serum samples were opportunistically collected from 12 counties in Arizona between February 2018 and November 2022. Immunofluorescence assays were employed to determine the anti-SFGR antibody titers in each of the samples, with dilutions ≥ 1:64 considered positive. An exponential nonlinear regression was used to determine the association between canine SFGR seroprevalence and human RMSF case rates per 100,000 as reported by the Arizona Department of Health Services.
resultsOf the 423 dogs sampled, 21% (89/423) were found to be positive for anti-SFGR antibodies. Eight of the 12 counties had seropositive dogs. Geometric mean titers ranged from 64 to 464, with a median of 179. A nonlinear regression model demonstrated a strong association between canine SFGR seropositivity and human RMSF case rates, with the best-fitting model employing RMSF case rates lagged by 1 year. A similar model also showed a significant association between canine SFGR geometric mean titers and RMSF case rates.
conclusionCanine SFGR seroprevalence correlates with human RMSF case rates, with RMSF risk rising exponentially as canine SFGR seroprevalence increases. This lends support to the potential use of canine SFGR serology as an epidemiological tool for forecasting RMSF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.